Clinical Trial: Efficacy and Influencing Factors of Secukinumab in Patients With Axial Spondyloarthritis

U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07130331) titled 'Efficacy and Influencing Factors of Secukinumab in Patients With Axial Spondyloarthritis' on Aug. 12.

Brief Summary: This study aimed to explore the efficacy and influencing factors of secukinumab in axSpA patients by conducting a real-world retrospective analysis.

Study Start Date: June 01, 2020

Study Type: OBSERVATIONAL

Condition: Axial Spondylarthritis (axSpA) Secukinumab

Intervention: DRUG: Secikinumab

secukinumab 150 mg at weeks 0, 1, 2, 3, and 4, followed by 150 mg s.c. every 4 weeks

Recruitment Status: COMPLETED

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Published by HT ...